Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6
暂无分享,去创建一个
J. Doudna | S. Wyman | M. Ott | A. Syed | R. Suryawanshi | A. Ciling | M. Khalid | B. Sreekumar | G. R. Kumar | T. Y. Taha | T. Tabata | I. Chen | M. Montaño | J. Hayashi | C. Tsou | Keith Walcott | Gabriella R. Kimmerly | Hannah S. Martin | Bryan H. Bach | Bryan H Bach | Gabriella R Kimmerly
[1] A. Ensser,et al. Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation , 2023, Nature.
[2] A. Ensser,et al. Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron , 2022, bioRxiv.
[3] Hao Tan,et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir , 2022, bioRxiv.
[4] J. Zahradník,et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 , 2022, Cell.
[5] Rommie E. Amaro,et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors , 2022, bioRxiv.
[6] Qian Wang,et al. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75 , 2022, bioRxiv.
[7] Fei Shao,et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.
[8] P. Klenerman,et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum , 2022, Cell.
[9] J. Zahradník,et al. Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5 , 2022, bioRxiv.
[10] M. Diamond,et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 , 2022, Nature.
[11] Arvind H. Patel,et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein , 2022, bioRxiv.
[12] Samuel S. Shepard,et al. SARS-CoV-2 Delta–Omicron Recombinant Viruses, United States , 2022, Emerging infectious diseases.
[13] L. Giaquinto,et al. The role of NSP6 in the biogenesis of the SARS-CoV-2 replication organelle , 2022, Nature.
[14] K. Ishii,et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike , 2022, Cell.
[15] M. Beer,et al. The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype , 2022, bioRxiv.
[16] A. Baiker,et al. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models , 2022, Virology Journal.
[17] J. Andriesen,et al. High Asymptomatic Carriage With the Omicron Variant in South Africa , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] D. Guo,et al. Reverse genetics systems for SARS‐CoV‐2 , 2022, Journal of medical virology.
[19] P. Fournier,et al. Culture and identification of a “Deltamicron” SARS‐CoV‐2 in a three cases cluster in southern France , 2022, medRxiv.
[20] A. Stern,et al. Drivers of adaptive evolution during chronic SARS-CoV-2 infections , 2022, Nature Medicine.
[21] Vineet D. Menachery,et al. A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions , 2022, Nature Communications.
[22] Ruhong Yan,et al. Omicron adopts a different strategy from Delta and other variants to adapt to host , 2022, Signal Transduction and Targeted Therapy.
[23] B. Luan,et al. Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice , 2022, bioRxiv.
[24] Frances E. Muldoon,et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.
[25] A. Kaneda,et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant , 2022, Nature.
[26] M. Kemp,et al. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition , 2022, Cell Research.
[27] R. Shafer,et al. Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function , 2022, bioRxiv.
[28] T. House,et al. OMICRON-ASSOCIATED CHANGES IN SARS-COV-2 SYMPTOMS IN THE UNITED KINGDOM , 2022, medRxiv.
[29] K. To,et al. The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity, transmissibility, and fitness in the golden Syrian hamster model , 2022, bioRxiv.
[30] Y. Kawaoka,et al. Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters , 2022, bioRxiv.
[31] K. To,et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron , 2021, Nature.
[32] Nasser,et al. Virological characteristics of the novel SARS-CoV-2 Omicron variants 1 including BA . 2 , 2022 .
[33] T. Ndung’u,et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.
[34] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[35] J. Nie,et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron , 2021, Emerging microbes & infections.
[36] L. Weinberger,et al. Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance , 2021, Cell.
[37] Y. Liu,et al. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus , 2021, Journal of travel medicine.
[38] J. Doudna,et al. Rapid assessment of SARS-CoV-2–evolved variants using virus-like particles , 2021, bioRxiv.
[39] D. O’Connor,et al. Acute SARS-CoV-2 infections harbor limited within-host diversity and transmit via tight transmission bottlenecks , 2021, PLoS pathogens.
[40] A. Pyke,et al. A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses , 2021, Nature Communications.
[41] M. Shi,et al. A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery , 2021, Virologica Sinica.
[42] J. Todd,et al. SARS-CoV-2 within-host diversity and transmission , 2021, Science.
[43] D. Robertson,et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research , 2021, PLoS biology.
[44] Vineet D. Menachery,et al. Engineering SARS-CoV-2 using a reverse genetic system , 2021, Nature Protocols.
[45] Benji C. Bateman,et al. Correlative Multi-scale Cryo-imaging Unveils SARS-CoV-2 Assembly and Egress , 2021, Research square.
[46] Carl A. B. Pearson,et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.
[47] G. Lohman,et al. Rapid 40 kb genome construction from 52 parts , 2020, bioRxiv.
[48] Jiaxing Zhang,et al. A novel cell culture system modeling the SARS-CoV-2 life cycle , 2020, bioRxiv.
[49] E. Koonin,et al. Ongoing Global and Regional Adaptive Evolution of SARS-CoV-2 , 2020, bioRxiv.
[50] W. Kamitani,et al. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction , 2020, bioRxiv.
[51] Vladimir Potapov,et al. Enabling one-pot Golden Gate assemblies of unprecedented complexity using data-optimized assembly design , 2020, PloS one.
[52] Ralf Bartenschlager,et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.
[53] F. Almazán,et al. Rescue of SARS-CoV-2 from a single bacterial artificial chromosome , 2020, bioRxiv.
[54] D. Fremont,et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. , 2020, SSRN.
[55] Zhigang Wu,et al. Molecular Architecture of the SARS-CoV-2 Virus , 2020, Cell.
[56] Shinji Makino,et al. An Infectious cDNA Clone of SARS-CoV-2 , 2020, Cell Host & Microbe.
[57] J. Rocklöv,et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.
[58] J. Sidney,et al. Cellular immune selection with hepatitis C virus persistence in humans , 2005, The Journal of experimental medicine.
[59] G. Davies,et al. Knowns and Unknowns , 2003 .
[60] R. Baric,et al. Systematic Assembly of a Full-Length Infectious cDNA of Mouse Hepatitis Virus Strain A59 , 2002, Journal of Virology.
[61] Michael Bunce,et al. Evolution and transmission of stable CTL escape mutations in HIV infection , 2001, Nature.
[62] E. Gould,et al. Infectious transcripts of tick-borne encephalitis virus, generated in days by RT-PCR. , 1995, Virology.
[63] Rolf M. Zinkernagel,et al. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo , 1990, Nature.
[64] P. Ahlquist,et al. cDNA cloning and in vitro transcription of the complete brome mosaic virus genome , 1984, Molecular and cellular biology.